semaglutide and medullary thyroid cancer Ozempic carries an FDA black box warning for carcinoma. Over 1,800 lawsuits are consolidated in federal MDL litigation with >$2 billion projected liability — primarily for gastroparesis, intestinal blockage, gallbladder medullary thyroid carcinoma semaglutide GLP-1

Potential Side Effects and Safety Considerations The most common side effects are gastrointestinal symptoms nausea, vomiting, and diarrhoea typical of GLP-1 receptor agonism

Semaglutide drugs have been shown to promote a weight loss of about 15% of the initial weight

Most patients begin experiencing appetite suppression within 37 days of starting semaglutide, with noticeable weight loss typically appearing within 24 weeks

Conversely, GT has been demonstrated to have pro-oxidant effects

Crucially, glucagon receptor activation increases energy expenditure and promotes preferential utilization of fat stores, creating a metabolic environment optimized for fat oxidation rather than muscle catabolism